John P. Leonard, MD @JohnPLeonardMD Twitter profile

Pinned Tweet

John P. Leonard, MD

4 years

Here is the big #hairstylesforheroes "reveal" - Nearly $75,000 raised to support the efforts our front line care team! Thanks to all who have supported and not too late to donate! Lots of great looks! #WCMDeptofMed @WeillCornell

22

23

300

Last Seen Profiles

@BGenniss1222

@lumontenegro7

@R1_Adv

@sma_sevincnur

@pengen_stw

@sora_koukan

@Evikocell

@SagalAshour

@ssloveloveww

@ManuMercurial

@bokeplokalmalam

@Pasmudnewbie231

@ColoradoCollege

@JoyPoos

@DrRaWanAhMed2

@GozdeMstf

@ResidentofGSK

@tpdcalisani

@HiroakiGoto1

@busra_dul

@Karthik_mathumi

@Wachiko

@Isaiah21P

@zagaika777

@fhlalymnab1

@MJled

@HomesteadP8

@nudeinterlude

@bambinodelmundo

@shinshogun_

@TheMrLillyShow

@woodyeeeee

@BAKUHATSUO

@ViralVortexxx

@teuk_gyu

@Sandy4STEAM

John P. Leonard, MD

@JohnPLeonardMD

3 years

A lymphoma version of "scientific papers" with apologies to and acknowledgment of @xkcdComic

17

65

335

John P. Leonard, MD

@JohnPLeonardMD

6 years

I prefer more slides with less data per slide rather than fewer slides jam packed with multiple miniscule figures #ASH18

8

21

228

John P. Leonard, MD

@JohnPLeonardMD

2 years

Lots of “first class” hematologists sitting in coach! #ASH22 ⁦ @ASH_hematology ⁩

5

4

199

John P. Leonard, MD

@JohnPLeonardMD

4 years

This says a lot......

Adam Phillippy

@aphillippy

4 years

Throwback to 5 years ago when Tony Fauci, at 74 yo, was suiting up to treat an Ebola patient himself because he "wanted to show his staff that he wouldn't ask them to do anything he wouldn't do himself". This is what leadership looks like.

886

32K

122K

1

29

178

John P. Leonard, MD

@JohnPLeonardMD

3 years

You can learn far more about clinical research (and help patients more) by designing, conducting and analyzing clinical trials than you do by reading (or posting) tweets about them

8

14

170

John P. Leonard, MD

@JohnPLeonardMD

4 years

7 pm on York Avenue between 68 and 70th street in NYC.....2/3 of the people on the street are nurses reporting for their shift @nyphospital @WeillCornell - much appreciation and admiration....

0

14

145

John P. Leonard, MD

@JohnPLeonardMD

5 years

Rather than a power nap pod, I think I would prefer being able to get a banana or coffee without a long line...I know a few NYC street vendors who could resolve this very well.... #ASH19

11

6

130

John P. Leonard, MD

@JohnPLeonardMD

6 years

I have admiration for #ASH18 speakers who are presenting in their non-native language (English) - for some no doubt not easy but important contributions to the meeting

4

20

129

John P. Leonard, MD

@JohnPLeonardMD

5 years

“Why is it that most of those who are successful think it is all their doing” - great discussion ⁦ @PreetBharara ⁩ that touches many aspects of our society and politics

‎Stay Tuned with Preet: What is Justice? (with Michael Sandel) on Apple Podcasts

‎Show Stay Tuned with Preet, Ep What is Justice? (with Michael Sandel) - Aug 22, 2019

podcasts.apple.com

8

25

117

John P. Leonard, MD

@JohnPLeonardMD

3 years

For immunocompromised individuals getting a 3rd "booster" COVID vaccine: DO NOT ASSUME that the "booster" necessarily solves potential problem of lower immunity against COVID (it doesn't for many) - need to speak w/your MD/team and often mask, distance etc - no false reassurance!

6

19

126

John P. Leonard, MD

@JohnPLeonardMD

4 years

A good rule of thumb is to pay attention to the doctor who has more patients with than tweets about a disease....

3

15

124

John P. Leonard, MD

@JohnPLeonardMD

5 years

Happy and proud that our team and medical center has helped to bring forward these important/impactful phase 3 findings for patients with indolent #lymphoma demonstrating effects of adding lenalidomide to rituximab #NYTopHospital @nyphospital @WeillCornell

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed...

PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodu...

ascopubs.org

1

9

120

John P. Leonard, MD

@JohnPLeonardMD

4 years

Outstanding omelet station at the buffet at my #ASH20 breakfast meeting location - will come back tomorrow! #ASHFromHome

7

4

123

John P. Leonard, MD

@JohnPLeonardMD

4 years

My new zoom avatar #hairstylesforheroes

11

2

115

John P. Leonard, MD

@JohnPLeonardMD

6 years

Spent the beginning & end of a long day thinking about a longtime patient who died overnight - he taught & mentored many disadvantaged students & had a remarkable way of telling me on most visits that by helping him we were impacting many lives - a special man who will be missed

5

10

111

John P. Leonard, MD

@JohnPLeonardMD

2 years

A patient memorialized one of my frequent expressions

0

3

109

John P. Leonard, MD

@JohnPLeonardMD

5 years

Patient comes for second opinion with one lymphoma diagnosis rendered previously. Sees our team, diagnosed with another subtype with entirely different prognosis and less aggressive therapy needed. Expert #lymphoma pathologist review so important!

8

15

101

John P. Leonard, MD

@JohnPLeonardMD

3 years

Patient with new lymphoma, trying to get a PET scan to stage…….insurance representative (deciding on precertification for scan): “What stage is it?”…..Great question, wish I knew!

4

1

102

John P. Leonard, MD

@JohnPLeonardMD

5 years

My patient of 13 years says he has a PhD in Mantle Cell #lymphoma ....I think he is right—-guess that makes me his dissertation advisor

4

100

John P. Leonard, MD

@JohnPLeonardMD

7 years

I expect MDs to spend much more time explaining to #lymphoma patients why they are not CAR-T candidates than managing the very few who are

5

41

98

John P. Leonard, MD

@JohnPLeonardMD

3 years

The #ASH21 #LeonardList high impact #lymphoma abstract finalists

3

6

100

John P. Leonard, MD

@JohnPLeonardMD

6 years

We offer our patients innovative, state-of-the-art therapies - but sometimes just pulling up a chair and having a good talk is what can make the greatest impact

6

23

95

John P. Leonard, MD

@JohnPLeonardMD

3 years

If you are immunocompromised or otherwise high risk, right now it seems best to “hunker down” as best you can. Having unmasked contact with people with recent “negative” tests still has some risk as things can evolve….

2

24

93

John P. Leonard, MD

@JohnPLeonardMD

3 years

One of the most important things about work is working with good people

2

12

95

John P. Leonard, MD

@JohnPLeonardMD

4 years

I have said to many patients over the years that while you may miss/modify one important family holiday (e.g. being in the hospital) it is with the goal of sharing many more in the future....seems like similar approach very relevant now for many of us....

2

8

93

John P. Leonard, MD

@JohnPLeonardMD

3 years

Those who participate in clinical trials are heroes

Matthew Herper

@matthewherper

3 years

Bill Ludwig, patient who helped pioneer cancer immunotherapy at Penn, dies at 75 of COVID-19

3

19

56

3

9

89

John P. Leonard, MD

@JohnPLeonardMD

3 years

State laws restricting out of state video visits without licensure are absurd and frankly abusive to patients - at a point where some patients want to drive out of their home state to do a video visit from their car in a parking lot in another location where it is “legal”….

6

14

89

John P. Leonard, MD

@JohnPLeonardMD

1 year

Very proud of our former chief resident..and all of our residents….⁦ @WeillCornell ⁩ ⁦ @nyphospital ⁩

0

2

88

John P. Leonard, MD

@JohnPLeonardMD

6 years

Two patients meeting in clinic for first time - one local, one lives several states away - patient 1 offers to have patient 2 stay at her house to ease the burden - amazing how patients come together to try to help each other through things

0

8

86

John P. Leonard, MD

@JohnPLeonardMD

4 years

If she can fill out her ballot while getting a chemotherapy infusion WE have no excuses - VOTE!

0

11

83

John P. Leonard, MD

@JohnPLeonardMD

4 years

I treat patients with #lymphoma . There are several FDA-approved drugs for lymphoma that I have never treated a patient with, & some others I have rarely used. That said, I am glad that they ALL are available if/when my patients and I - together - decide they are a good option.

4

82

John P. Leonard, MD

@JohnPLeonardMD

3 years

Patient with mantle cell #lymphoma .....over 12 year history, 2 lines of treatment on trials, doing well....never has had chemotherapy....the world is changing....

2

3

81

John P. Leonard, MD

@JohnPLeonardMD

5 years

Why does a twitter chat need a pharma sponsor?

MDedge Hematology & Oncology

@MDedgeHemOnc

5 years

Sponsored: Join us for a Twitter chat on #CLL during #ASH19 on Dec. 10th at 6 PM EST with @anthonymatomd and @chadinabhan on #MDedgeChats .

0

4

11

14

83

John P. Leonard, MD

@JohnPLeonardMD

6 years

The terms “shows promise” and “promising” in regard to a new drug or treatment regimen are non-scientific and frankly useless. Real advances don’t need to be described in this way, the data tell the story.

7

27

77

John P. Leonard, MD

@JohnPLeonardMD

6 years

With respect to hard work of all involved in these lymphoma CAR-T studies, and importance of data to the community, if they going to be presented over and over at every meeting there should be a clear description of what is new/incremental info and time frame that is new #ASCO18

3

12

76

John P. Leonard, MD

@JohnPLeonardMD

5 years

Just recorded the #ASH19 #LeonardList edition of our ⁦ @WeillCornell ⁩ #CancerCast podcast highlighting 10 key #lymphoma abstracts - next week the episode (with my commentary on these + 5 bonus extra pod-only abstracts) will drop and the 10 day twitter countdown will begin!

2

8

76

John P. Leonard, MD

@JohnPLeonardMD

2 years

Back from speaking at the Haematology Association of Ireland meeting - great people, scenery, history….and Guinness

3

1

75

John P. Leonard, MD

@JohnPLeonardMD

3 years

Is there an ICD 10 code for “Questions prompted by New York Times article” ?

4

71

John P. Leonard, MD

@JohnPLeonardMD

5 years

“When 90% of #lymphoma are not ‘Hodgkin’ ...why do we call them ‘non-Hodgkin’? Maybe we should change the name....” - B Cheson

5

13

74

John P. Leonard, MD

@JohnPLeonardMD

8 years

Why we do what we do

0

11

67

John P. Leonard, MD

@JohnPLeonardMD

2 years

Seems like a higher percentage of the people in the room at the start of the #lymphoma #CLL session at #ASCO22 could have stayed in the room to hear the presentations on the important issue of healthcare disparities in these conditions

2

14

71

John P. Leonard, MD

@JohnPLeonardMD

4 years

Fun

WCM Englander Institute for Precision Medicine

@WCMEnglanderIPM

4 years

Please join us in congratulating @EngIPM Member John. P. Leonard, M.D. ( @JohnPLeonardMD ) on his appointment today as Senior Associate Dean for Innovation and Initiatives @WeillCornell ! #CancerResearch #PrecisionMedicine

8

6

57

5

71

John P. Leonard, MD

@JohnPLeonardMD

5 years

Manuscript now online @JCO_ASCO AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed...

PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodu...

ascopubs.org

2

25

64

John P. Leonard, MD

@JohnPLeonardMD

6 years

Just saw a mantle cell lymphoma patient diagnosed 10 years ago - still in remission from our initial therapy on a clinical trial...he and his wife reminisced about all (good) that has happened in their life during that time...

4

6

68

John P. Leonard, MD

@JohnPLeonardMD

3 years

The #ASH21 #LeonardList high impact #lymphoma abstract list is finalized & under tight security (my backpack)! Countdown daily 12/1 to 12/10 or listen to the #cancercast podcast review (with 5 extra bonus selections) recorded & expected to drop on 12/1.

John P. Leonard, MD

@JohnPLeonardMD

3 years

The #ASH21 #LeonardList high impact #lymphoma abstract finalists

3

6

100

0

8

68

John P. Leonard, MD

@JohnPLeonardMD

6 years

Great to have 2 daughters, in college in different cities, both marching in #WomensMarch2018

3

65

John P. Leonard, MD

@JohnPLeonardMD

6 years

A patient brings us fresh-picked blueberries, my physician assistant turns them into muffins, I eat - we are truly a multidisciplinary collaborative team in our clinic (excuse my purple fingers)

3

2

66

John P. Leonard, MD

@JohnPLeonardMD

7 years

Just went upstairs and saw my #lymphoma patient's newborn baby - a good day @nyphospital @WeillCornell

0

4

64

John P. Leonard, MD

@JohnPLeonardMD

2 years

BM biopsies unnecessary for most situations in follicular #lymphoma clinical trials - eliminate study requirements & easier for patients! Congratulations ⁦ @drsarahruth ⁩ & ⁦ @ALLIANCE_org ⁩ ⁦ @SWOG ⁩ ⁦ @eaonc ⁩ ⁦ @theNCI ⁩ colleagues

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National...

PURPOSE Bone marrow biopsies (BMB) are performed before/after therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. We sought to establish whether BMB add value in...

ascopubs.org

5

12

66

John P. Leonard, MD

@JohnPLeonardMD

5 years

Patient with recurrent follicular lymphoma doing well on current treatment: “Maybe I should have had this back at the beginning” - the drug hadn’t yet been developed 15 years ago when she was diagnosed - shows the benefits of progress we are making!

5

65

John P. Leonard, MD

@JohnPLeonardMD

4 years

Think about the fact that despite the flaws of the US Postal Service, any person can - for 55 cents - have an envelope and contents delivered across the country a few days later door to door. This is impressive, important and should be protected and not messed around with.

3

2

65

John P. Leonard, MD

@JohnPLeonardMD

2 years

Today I had to tell 2 patients requesting a telemedicine consult that I am unable because I am not licensed in their home states. And this is good why???

6

4

67

John P. Leonard, MD

@JohnPLeonardMD

5 years

Over 100 #ASH19 @ASH_hematology abstracts identified by keyword search “real world” - are the others from the “unreal world” ? And do abstracts from authors working at major academic referral centers and pharma companies represent the “real world”?

8

65

John P. Leonard, MD

@JohnPLeonardMD

4 years

“There cannot be greater rudeness than to interrupt another in the current of his discourse.” - John Locke

2

11

65

John P. Leonard, MD

@JohnPLeonardMD

3 years

After about 20 years of work in “cell of origin directed” strategies in upfront and relapsed DLBCL #lymphoma it seems like the newest advances are “cell of origin agnostic” - there are important lessons here….

4

9

64

John P. Leonard, MD

@JohnPLeonardMD

6 years

As a community in lymphoma, we should be embarrassed by the lack/limitations of quality of life data available on treatments - it is pretty sad that we cannot currently provide solid data to guide choices - we need to do better and collaborate w experts with novel tools #ASCO18

6

24

61

John P. Leonard, MD

@JohnPLeonardMD

5 years

Intrathecal prophylaxis in DLBCL #lymphoma seems to treat the doctor's worries more than the patient's risk of CNS relapse.....

1

22

63

John P. Leonard, MD

@JohnPLeonardMD

3 years

Those who care about progress for patients and advances in treatment need to be aware of the staffing challenges in clinical research programs across the country - that can be marginally funded in the best of times - multiple strategies needed to support studies of new therapies

3

9

64

John P. Leonard, MD

@JohnPLeonardMD

2 years

Removing bone marrow biopsies from follicular #lymphoma clinical trials - largely not needed - good for patients! ⁦ @drsarahruth ⁩ ⁦ @ALLIANCE_org ⁩ ⁦ @theNCI ⁩ ⁦ @WCMLymphoma ⁩

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National...

PURPOSE Bone marrow biopsies (BMB) are performed before/after therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. We sought to establish whether BMB add value in...

ascopubs.org

1

14

64

John P. Leonard, MD

@JohnPLeonardMD

1 year

Dr. Peter Martin “ketching up” in clinic

2

0

64

John P. Leonard, MD

@JohnPLeonardMD

3 years

Diffuse large B cell #lymphoma therapy is improving (and getting more complicated)! Clinical trials are the engine! Greater participation and faster enrollment are the keys to rapid progress and saving/improving more lives! #ASH21

0

11

62

John P. Leonard, MD

@JohnPLeonardMD

5 years

My editorial comments in @JCO_ASCO on the PHOENIX study of Ibrutinib + R-CHOP in Diffuse Large B Cell #Lymphoma :De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology

De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology

ascopubs.org

4

18

62

John P. Leonard, MD

@JohnPLeonardMD

4 years

So the CAR-T debate of which works better/is less toxic is now going to be rivaled by the bispecific antibody debate of which works better/is less toxic.... #ASH20

4

2

63

John P. Leonard, MD

@JohnPLeonardMD

4 years

It’s very easy to criticize a clinical trial’s design when you know the results

2

62

John P. Leonard, MD

@JohnPLeonardMD

3 years

Kudos to everyone who did the hard work (and the patients who participated) for the studies to be presented at #ASH21 - most importantly to advance knowledge and patient care - participating in research is the way to improve outcomes

0

2

60

John P. Leonard, MD

@JohnPLeonardMD

3 years

One of several exciting bispecific antibodies for B cell lymphoma - seems likely that a few years from now many more patients will be receiving bispecifics than CAR-T....

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable...

PURPOSE Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated...

ascopubs.org

4

17

62

John P. Leonard, MD

@JohnPLeonardMD

4 years

Six new physicians recently added to the Heme/Med Onc team @WeillCornell @nyphospital - we are growing and expanding our clinical and research programs under @DrMhidalgo - exciting progress!

0

61

John P. Leonard, MD

@JohnPLeonardMD

6 years

Key point-for clinical trials in follicular & DLBCL #lymphoma there is NO NEED to do BM biopsies to assess response! Changes response in <1% of enrolled pts. Lets do patient friendly trials & do BM bx only if needed for valid clinical/correl science reasons! #LeonardList #ASH18

John P. Leonard, MD

@JohnPLeonardMD

6 years

Now for #LeonardList key #ASH18 #lymphoma abstract number 8 - 1605 Rutherford @drsarahruth - Bone marrow biopsies do not meaningfully change response assessments in follicular and DLBCL #lymphoma clinical trials (from GALLIUM and GOYA studies) w/2600 pts

1

12

25

2

19

57

John P. Leonard, MD

@JohnPLeonardMD

2 years

Remembering a special person and close colleague with a new lectureship @weillcornell @WCMLymphoma

0

8

58

John P. Leonard, MD

@JohnPLeonardMD

5 years

Happy to see a follicular #lymphoma patient today in clinic who I have cared for over 20 years (since I was a brand new attending)! Made us both feel old, but both aiming for the next 20 plus years!

0

57

John P. Leonard, MD

@JohnPLeonardMD

4 years

If a doctor can have a serious conversation with a patient and family through 2 masks and a face shield, a football coach can keep his cloth mask up to scream at a referee...

1

4

59

John P. Leonard, MD

@JohnPLeonardMD

3 years

Pretty soon we should be comparing bispecific ab (alone or in combo) randomized vs CAR-T (w/crossover) in a number of #lymphoma settings….though I expect biases (in both directions) may preclude such depending on the situation #ASH21

9

14

59

John P. Leonard, MD

@JohnPLeonardMD

3 years

One of the best things about an in person scientific meeting is being able to turn to insightful and respected colleagues nearby and ask “what do you think of that study?” - here’s hoping for a healthy dose of those exchanges in some form at #ASH21

0

1

57

John P. Leonard, MD

@JohnPLeonardMD

8 years

Unless it is a "parachutes and planes" single arm trial you probably should not claim you improved survival w/o control arm #ASH16

1

28

57

John P. Leonard, MD

@JohnPLeonardMD

3 years

Big day today ⁦ @WeillCornell ⁩

0

3

59

John P. Leonard, MD

@JohnPLeonardMD

4 years

Regardless of my haircut, I #MaskUp to protect my patients, colleagues, family & friends, & myself. This is especially important to all of us at @WeillCornell @nyphospital I challenge @BrendonStilesMD @mdmanishshah @DrMhidalgo @drallysonocean @FeliceSchnoll to show their masks

0

5

58

John P. Leonard, MD

@JohnPLeonardMD

6 years

Black Friday: The annual day when hematologists overwhelm barbershops and hair salons to get their pre #ASH18 haircuts (ok it may extend over a few days but lots get pre-ASH cuts - see if you can guess at the meeting....)

10

3

54

John P. Leonard, MD

@JohnPLeonardMD

6 years

So we had the pre- #ASH18 haircut, the busy meeting, and now the cycle continues with.... wait for it....the post-ASH respiratory virus (fostered by air travel) ....no doubt there are plenty of them out there...or coming soon...🙁 @ASH_hematology

6

2

52

John P. Leonard, MD

@JohnPLeonardMD

5 years

Patients are sick of hearing about, thinking about, worrying about and dealing with concerns about measles. It is ridiculous that we are at this point. Totally avoidable. The amount of energy that has had to be devoted to this issue could be better spent on many other things.

2

11

54

John P. Leonard, MD

@JohnPLeonardMD

6 years

Seeing a patient in mid 80s who I have followed (never treated) for 2 years (over 9 visits) with an asymptomatic DLBCL that hasn't progressed (she smartly declined rx). Me: "See you in 6 months" Her: "If you don't see me it means I died" So much to learn from this encounter....

3

11

54

John P. Leonard, MD

@JohnPLeonardMD

5 years

FDA approves Polatuzumab in combination with B-R for patients with relapsed or refractory diffuse large B-cell lymphoma

FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse...

FDA approves chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma

www.fda.gov

1

22

55

John P. Leonard, MD

@JohnPLeonardMD

4 years

I had a headache this am. Took ibuprofen. I know it has possible side effects, sometimes serious. My headache got better. Not sure if it was due to the ibuprofen or if it would have gotten better anyway. No OS benefit. No formal QOL analysis. I’m glad ibuprofen is available.

7

3

53

John P. Leonard, MD

@JohnPLeonardMD

4 years

Seems unlikely every B cell lymphoma patient will ultimately get a CAR-T, but seems more likely that every B cell lymphoma patient will get a bispecific antibody..... #ASH20

4

2

54

John P. Leonard, MD

@JohnPLeonardMD

6 years

Tomorrow begins #LeonardList twitter countdown of 10 top #ASH18 lymphoma abstracts - BUT anyone wanting to hear my comments on the full #LeonardList (+ 5 podcast-only bonus picks) they are now live on #CancerCast - feedback welcome via twitter #LeonardList

2

10

51

John P. Leonard, MD

@JohnPLeonardMD

6 years

Despite our challenges, frustrations, disappointments and anger - it is important to keep in mind that there are a lot of people working hard in different ways to make the world better - and lots of opportunities for all of us to do so - big and small

1

11

51

John P. Leonard, MD

@JohnPLeonardMD

4 years

“A coward is incapable of exhibiting love; it is the prerogative of the brave.” - Mahatma Gandhi

0

8

54

John P. Leonard, MD

@JohnPLeonardMD

3 years

Over 25 years after the important publication by Margaret Shipp and colleagues of the International Prognostic Index (IPI), we now have reached a point where we will treat Diffuse Large B Cell #lymphoma patients differently based on their IPI scores #ASH21

5

9

54

John P. Leonard, MD

@JohnPLeonardMD

4 years

I need a haircut! We’re launching the #HairstylesForHeroes campaign to support #WCMDeptOfMed junior faculty & trainees. I’ll sport a crazy hairstyle (? mullet, mohawk, dye) once we meet our fundraising goal. Donate & help spread awareness. #TogetherWithWCM

3

6

55

John P. Leonard, MD

@JohnPLeonardMD

4 years

The first step is to achieve a remission. The next goal is then to reach a cure.

1

0

53

John P. Leonard, MD

@JohnPLeonardMD

3 years

Medicine is a science of uncertainty and an art of probability. — Sir William Osler

1

9

53

John P. Leonard, MD

@JohnPLeonardMD

6 years

The “lymphoman water bottle” - wish I’d thought of it!

4

0

50

John P. Leonard, MD

@JohnPLeonardMD

4 years

Glad to see we are removing requirements for bone marrow biopsy in many #lymphoma clinical trials! Usually not essential and more patient-friendly!

5

8

52

John P. Leonard, MD

@JohnPLeonardMD

3 years

Whether virtual or in person, have to do the pre #ASH21 haircut

4

1

52

John P. Leonard, MD

@JohnPLeonardMD

4 years

It is wonderful to hear an inspiring speech from a leader you can respect, believe and have pride in

1

53

John P. Leonard, MD

@JohnPLeonardMD

1 year

The Fauci Selfie

0

2

51

John P. Leonard, MD

@JohnPLeonardMD

6 years

Would be reasonable to run randomized or pragmatic trial of now standard EHR (eg Epic) vs streamlined version w less detail (fewer checkboxes largely for billing) w/endpoints of clinical outcomes, patient satisfaction & MD/RN/provider QOL @cuttingforstone

4

19

52

John P. Leonard, MD

@JohnPLeonardMD

4 years

Remember my first day as intern/on call night. 30 yrs ago today. To my resident’s horror I “renewed” my patients’ orders by d/cing every medication & reordered them all. Thought was the way to do it. That night I lost my papers w/everyone’s sign out info. Days of the giants.

1

52

John P. Leonard, MD

@JohnPLeonardMD

4 years

Just finalized the #ASH20 #LeonardList of top 10 #lymphoma abstracts - lots of great studies - daily annual countdown starts wednesday & we just recorded #Cancercast podcast to post soon with 5 additional bonus selections & my comments. Looking forward to feedback and dialogue!

0

3

52

John P. Leonard, MD

@JohnPLeonardMD

3 years

In clinic today post #ASH21 - what is crystal clear on new data on diffuse large B cell #lymphoma is that often choice not "crystal clear" - pts don't fit into neat boxes/algorithms - good care requires a patient-centered discussion & wisdom in applying data to individuals

0

6

51